Mitotherapeutix develops siRNA-based drugs that focus on addressing difficult disease targets. Mitotherapeutix targets and controls the metabolic activity in the mitochondria helping in the treatment of kidney, immune, and liver diseases. Mitotherapeutix's drug candidates MT-001 to MT004 are in the early stage of the preclinical study. The company is targeting diseases like Unilateral Ureter Obstruction, acute liver failure, CD8 T-cells, and its role in treating diseases like cancer among others. The company is using proprietary technology to target the beta-oxidation pathway in the mitochondria.Something looks off?